| Autor: |
Sai Akshaya Hodigere Balasubramanya, Sumit Agarwal, Sooryanarayana Varambally, Balabhadrapatruni V. S. K. Chakravarthi, Chong-Xian Pan, Guru Sonpavde, James E. Ferguson, Upender Manne, Alyncia D. Robinson, Gurudatta Naik, Darshan S. Chandrashekar, George J. Netto, Saroj Nepal, Hasibur Rehman, Marie-Lisa Eich |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Metastatic urothelial carcinoma of the bladder is generally incurable by current systemic therapy. Molecular characterization of bladder cancer (BLCa) has revealed multiple candidate driver genes for BLCa tumorigenesis. Epigenetic/chromatin modifiers have been shown to be frequently mutated in BLCa, with ARID1A mutations highly prevalent in nearly 20% of early and late stage tumors. EZH2 is a histone methyltransferase that acts as an oncogene. The data herein show that ARID1A deficient tumors, but not ARID1A wild-type tumors are sensitive to EZH2 inhibition. Specifically, EZH2 inhibitor-treated ARID1A deficient bladder cancer cells show significantly reduced cell viability, colony formation, and in vivo tumor growth relative to ARID1A-wild type bladder cancer cells. Thus, our study suggests that a specific subset of bladder cancer patients with ARID1A mutations can be therapeutically treated with pharmacologic inhibitors targeting EZH2. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
